Alex Lash on Muck Rack

Alex Lash

San Francisco
National Biotechnology Editor — Xconomy
As seen in: Xconomy

I'm the national biotech editor at @Xconomy, where I cover biomedicine, business, and policy. I'm also the editor of @TheFrisc, where I cover my hometown.

Search Tweets

Twitter Feed

@alexlash — 5,129 followers, 2,219 tweets

Nov 16, 2017

Following up on my September feature on @seattlechildren CAR-T pediatric ALL program, which aims to cut relapse after current treatments, including Kymriah. Another study in the complicated scheme can start recruiting, per today's FDA go-ahead.

Nov 14, 2017

ICYM Friday (because I was in transit & forgot to tweet it): $JUNO explained to some extent what went wrong in its JCAR015 ROCKET trial. Officials also took the opportunity to promise a return to adult ALL with its JCAR017 product.

Nov 14, 2017

The first blockbuster deal of the genetic-targeted, organ-agnostic cancer era. @BentheFidler reports on Loxo's $400M payday courtesy of Bayer... umm... it's going to take some time to get used to all these extra characters. $LOXO

Nov 07, 2017

Finally getting to this. Final chart shows the public will to boost gun safety and reduce deaths.

Show More